Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. METHODS: In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point). RESULTS: A total of 272 participants underwent randomization. At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9. At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures. The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts. The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class. CONCLUSIONS: Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“Between 65% and 96% of participants taking orforglipron achieved an A1C level below 7.0% at 26 weeks.174”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [174]
In the citing paper
“In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to −14.7% compared to −2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [25]
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“In a multicenter phase 2 trial, 272 participants (mean age, 54.2 years; mean BMI, 37.9 kg/m 2 ) were randomly assigned to 1 of 4 doses of oral orforglipron (12, 24, 36, or 45 mg) once daily or placebo, for 36 weeks (Wharton et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Self-citationDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Self-citationLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Cited by
Items 301–400 of 509
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 2
“Other innovations include developing potentially more acceptable formulations of GLP-1 receptor agonists such as monthly injectable maridebart cafraglutide [70] or oral orforglipron [71].”
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
“The phase 2 obesity trial by Wharton et al. first established proof of concept, showing dose-dependent weight reduction over 36 weeks, but the phase 3 Wharton, Blevins [38] trial provides the stronger obesity-specific evidence because of its larger sample size and 72-week duration.”
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
Raddatz, D. (2023) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-023-00170-3 · Cited by 2
“Ähnlich wie bei anderen GLP-1-RA war dieser Gewicht-verlust begleitet von einer Verbesserung wichtigerkardiometabolischenParameter, aber auch von Übelkeit, vor allem bei zu schneller Dosiseskalation [14].”
BackgroundBeyond pounds: What else could be lost?
Idrees, T., & Umpierrez, G. E. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108649 · Cited by 2
Chang, S., Song, D., Oh, S., Han, S.-A., Jung, J.-M., Song, N., Kang, H. G., Lee, S., Ahn, J., Ahn, S., et al. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106820 · Cited by 2
The Power and Perils of Electronic Health Record-Enabled Pragmatic Trials*
Maiga, A. W., DeMasi, S. C., Qian, E. T., Semler, M. W., & Casey, J. D. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006293 · Cited by 2
GLP-1 RAs: The newest powerhouse in metabolic medicine
Drake, E. S., Marino, A. B., Theroux, J. D., & Roberts, K. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000216 · Cited by 2
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 3
“[100].”
GLP-1 receptor agonists for weight loss, benefits and risks: A systematic review of the literature
de Moraes, D. S. P., & Estrín, M. A. (2024) · Salud Ciencia y Tecnología - Serie de Conferencias · doi:10.56294/sctconf2024.719 · Cited by 2
Obesidad, el papel del gastroenterólogo
Costa, V. A., Escobar, D. C., Kerguelen, A., Rodriguez, J., Rodriguez, A., & Neto, M. G. (2024) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.1192 · Cited by 2
Tu, Y., & Yu, H. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.99 · Cited by 5
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Suwabe, T., Torres, V. E., Vaughan, L. E., Madsen, C. D., Harris, P. C., Shimada, Y., Nakatani, S., Hoshino, J., Nishio, S., Mochizuki, T., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.12.019 · Cited by 2
Mi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
“Accumulating clinical studies have indicated that GLP-1RAs have positive effects on obesity, nonalcoholic fatty liver disease, diabetes, cardiovascular disease, etc. [36– 38].”
Kanu, C., Clucas, C., Skalicky, A. M., Samuelson, A., GOETZ, I. A., Neff, L. M., Boye, K. S., & Karn, H. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03386-2 · Cited by 3
“…agonist of GLP-1), tirzepatide (agonist of GIP and GLP-1 receptors), and retatrutide (investigational agonist of GIP, GLP-1, and glucagon receptors) may address obesity-associated appetite dysregulation to achieve substantial weight loss in adults with obesity or overweight [20–28].”
Pharmacotherapy of Type 2 Diabetes Mellitus
Jha, P. K., Shukla, H., Makwana, A., & Kakkad, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002309 · Cited by 4
Al‐Horani, R. A., Aliter, K. F., & Aliter, H. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998276832231124170324 · Cited by 5
Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
Seetharaman, R., & Pandit, S. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0234 · Cited by 2
Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
Seetharaman, R., & Pandit, S. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0172 · Cited by 1
GORD and GLP-1 receptor agonists: an emerging concern for gastroenterologists
Massey, B. T. (2023) · Gut · doi:10.1136/gutjnl-2023-331027 · Cited by 1
“14 There is also the possibility that GLP-1 RAs might promote reflux by other mechanisms, as GLP-1 release resulting from colonic fermentation of a meal containing indi-gestible carbohydrates is associated with an increase in postprandial reflux events in patients with GORD.”
BackgroundInfluentialNishimura, Y., Esaki, T., Isshiki, Y., Furuta, Y., Emura, T., Watanabe, Y., Ohta, M., Arai, S., Noda, H., Shimizu, M., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202300589 · Cited by 1
Incretins and the metabolic syndrome
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.020 · Cited by 1
Liu, X., Wang, X., Xie, M., & Cao, L. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14296 · Cited by 1
“GLP-1 receptor agonists are increasingly preferred by health-care professionals and overweight or obese patients with type 2 diabetes due to their capacity to reduce appetite, increase satiety, and to facilitate dietary management 20 – 22 .”
BackgroundThe transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Zhou, Y.-F., Li, Q., Wang, L.-G., Lu, Y., Wang, Y., & Yang, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00041-w · Cited by 1
“…of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig.”
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
Zhao, W., Yin, Y., Shi, Z., Yang, K., Li, X., Yang, Y., Jing, T., & Kang, Z. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11213-7 · Cited by 1
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Burr, E. F., Roytman, M., Poirier, É., Kolbuszewska, M. T., Pfaus, J. G., Komisaruk, B. R., Goldstein, I., & Rubin, R. S. (2025) · Sexual Medicine · doi:10.1093/sexmed/qfaf073 · Cited by 3
Rusznak, M., Sierra-Hernandez, D., Dupuy, C., Toki, S., Wu, A. Y., Rao, U. K., Abney, M., Zhang, J., Hu, Q., Warren, C. M., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf251 · Cited by 1
Box, M. W., Puga, T. B., Werthmann, N. J., Liu, Y., & Riehl, J. T. (2025) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-25-00312 · Cited by 1
“16-19 Although there has been literature evaluating the outcomes of GLP-1RA use in elective total hip arthroplasty (THA) 20-23 and total knee arthroplasty, 20,24,25 the literature remains scant, particularly in the trauma setting.”
Chen, S., Lobato, C. B., Wong, C., Manchanda, Y., Viloria, K., Davies, I., Andersen, D. B., Ast, J., Sloop, K. W., Hodson, D. J., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102304 · Cited by 2
“Indeed, it is postulated that the therapeutic performance in humans of two more recently developed GLP-1RAs — tirzepatide and orforglipron — depend partly on their avoidance of GLP-1R desensitisation or downregulation [22 — 25].”
Moura, N. S., Schledwitz, A., Cheng, K., Song, Y., Kwon, M. S., Cairns, C. A., Njei, L., Raufman, B., Drachenberg, C. B., Wang, J., et al. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00739.2025 · Cited by 1
GLP-1 Receptor Agonists: A New Hope in the Global Fight Against Obesity — Benefits and Health Risks
Pastuszek, O., Borowski, K., Radziwon, M., Bolesta-Okuniewska, E., Michalak, P., Marchwińska-Pancer, A., Kopeć, K., Ceryn, J., & Wicher, A. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.87.67433 · Cited by 1
Development of the Weight and Emotions Scale (WES)
Kanu, C., Kimel, M., GOETZ, I. A., Neff, L. M., Boye, K. S., Stefan, M., & Jordan, J. B. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70119 · Cited by 1
“agonist), and retatrutide (investigational agonist of GIP, GLP‐1, and glucagon receptors) have the potential to produce significant weight reduction in adults with obesity or overweight and improve HRQoL [14–23].”
Wei, J., Wang, L., Zebin, M., & Zhang, P. (2026) · Biology · doi:10.3390/biology15030233 · Cited by 1
“Increasing evidence indicates that GPCRs play critical roles in metabolic tissues, including the liver, gut, adipose tissue, and pancreatic islets, and serve as effective therapeutic targets for obesity, diabetes, and fatty liver disease [34–36].”
A potent novel small molecule GLP-1R agonist identified by rational design and CADD
Chen, J., Yao, Y., & Li, H. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118578 · Cited by 1
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Kim, M., Van, J. Y., Park, S., Hwang, J. Y., Seong, Y., Park, Y. J., Lee, S., Ryu, B., Jun, J. Y., Jung, W., et al. (2026) · Food Frontiers · doi:10.1002/fft2.70246 · Cited by 1
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
“Thera - peutic innovation now includes dual and triple incretin receptor agonists [4 – 7] as well as orally bioavailable small-molecule formulations [8, 9 ], reflecting ongoing efforts to enhance pharmacodynamic durability.”
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
“7,23,24 27 When neither lifestyle nor therapeutic agents are effective at managing obesity, bariatric/metabolic surgery is considered, particularly in cases of severe obesity and the presence of comorbidities.”
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
Ji, L., Gao, L., Dong, R., Yuan, M., Zhao, D., Pang, S., Zhao, J., Zhao, L., & Chen, W. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102743 · Cited by 2
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Nguyen, T., Hong, L., & Iso, T. (2026) · Cardiorenal Medicine · doi:10.1159/000552517 · Cited by 1
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Davies, M. J., Aroda, V. R., Rosenstock, J., Capehorn, M., Pedersen, S. D., Morizzo, E., Sonali, M., Johansson, P. A., Grice, D., Andersson, A., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00748-8 · Cited by 3
Self-citationEmara, A., Emara, M., Mansour, A., Elkholy, M., Abbas, O., Abdul‐Hafez, H. A., Azzawi, M. A. D. A., & Shubietah, A. R. M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02218-9 · Cited by 1
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
“More recent longer-term studies have suggested that orforglipron may achieve clinically relevant reductions in body weight and glycemic indices in patients with obesity and/or T2D, potentially approaching the ef fi cacy seen with established injectable incretin therapies (14 – 16).”
Alper, A., Fagin, A., Karthikeyan, A., Karp, A., Terashima, R., Murli, H., Gershon, A., & FAILLACE, R. T. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00814-4 · Cited by 1
Kamrul-Hasan, A. B. M., Ashraf, H., Nagendra, L., Khalil, I., Chatterjee, S., Dutta, D., Haq, T., Alanazi, M. A., & Pappachan, J. M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70181 · Cited by 1
“For orforgli-pron, 6–12 mg was treated as LoD, 24–36 mg as MeD, and 45 mg as HiD, aligning with the stepped escalation used in ATTAIN‐1 and earlier studies [23, 24].”
InfluentialBeniwal-Patel, P. M., Samaan, S., Abreu, M. T., Deepak, P., & Yarur, A. J. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izag151 · Cited by 2
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“Mechanistically, it preferentially activates G protein/cAMP signaling with reduced β - arrestin recruitment and receptor internalization [130].”
Toshikuni, N. (2026) · Metabolites · doi:10.3390/metabo16080586 · Cited by 1
“Oral incretin-based agents may improve accessibility and adherence, although their role in MASH requires dedicated studies [45].”
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“In parallel, oral small-molecule GLP-1 receptor agonists such as orforglipron may broaden treatment options by addressing route of administration and access-related barriers, although they should be considered separately from dual-or multi-receptor agonist strategies [45].”
Sztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.003 · Cited by 1
Intersections between HIV and obesity in emerging economies
Levi, J., Fairhead, C., & Hill, A. M. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000827 · Cited by 1
“42 www.co-hivandaids.com”
Bloomgarden, Z. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13568 · Cited by 1
Pharmacological Treatment of Obesity: A Review of Current and Future Methods
Lęgas, A., Smalira, J., Przybysz, B., Kawalec, J., Zawistowska, J., Rogowska, K., Pochodowicz, K., Rogala, W., Rutkowska-Kawalec, W., & Urbańska, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.22.54691 · Cited by 1
Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies
Vinson, A. J., & Matas, A. J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000726 · Cited by 2
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
“Danuglipron (35), a selective small‑molecule GLP1RA, and orforglipron, a non‑peptide GLP1RA, are also being developed as oral GLP1RAs for the treatment of obesity and T2DM (56).”
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“In phase 2 trials that included patients with obesity [85] and diabetes [86], the orforglipron group had significant change from baseline body weight (up to −12.6% at 24 weeks and up to −14.7% at 36 weeks) and significant decrease in hemoglobin A1c (up to − 2.1”
InfluentialObésité : entre pléthore thérapeutique et questionnements nécessaires
Halimi, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.013 · Cited by 1
SEMAGLUTIDE (OZEMPIC) A POTENT WEAPON IN THE FIGHT AGAINST OBESITY
Mukhtar, B. B. (2024) · Pakistan Postgraduate Medical Journal · doi:10.51642/ppmj.v35i01.694 · Cited by 1
Jung, M., Reisert, M., Rieder, H., Rospleszcz, S., Haueise, T., Pischon, T., Niendorf, T., Kauczor, H.-U., Völzke, H., Bülow, R., et al. (2025) · medRxiv · doi:10.1101/2025.05.23.25328227 · Cited by 1
“( 27 ) In research, our framework applied to routine imaging examinations could generate large clinical data sets for further studies, to better understand the role of body composition-derived z-scores for disease-specific risks and clinical outcomes.”
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
IDRIS, I. R. (2023) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.67
The promise of a new orally active body weight reducer
Volpe, M., & Pedicino, D. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad470
Review wetenschappelijk congres American Diabetes Assiociaton
presymptomatic, C. C. B. U. T. M. E. O. D. I., & T1D., S. 2. T. 1. D. (. A. T. T. E. I. O. I. U. R. S. 3. (2023) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-023-1223-6
Diabesity Treatments Today and Tomorrow
Pavlakis, G., & Goldman, J. D. (2023) · ADCES in Practice · doi:10.1177/2633559x231202497
Neuer GLP-1-Agonist bei Adipositas
(2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1986-1677
Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
Nauck, M. A. (2023) · Deutsches Ärzteblatt · doi:10.3238/persdia.2023.11.03.01
Effective Anti-Obesity Drugs Make Losing Weight a Big Deal
Williams, S. C. P. (2023) · Engineering · doi:10.1016/j.eng.2023.11.005
Management of obesity: Going beyond eating less and moving more
Podlasek, A. (2023) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380231221001
“Orforflipron is available as an oral preparation, in contrast with most other drugs in this class which are injectables (Jastreboff et al., 2023; Wharton et al., 2023).”
BackgroundIst eine höher dosierte orale Semaglutidtherapie sinnvoll?
Martin, S., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-023-01639-2
La medicina cardiometabolica nell’obesità
(2024) · il Diabete · doi:10.30682/ildia2304d
“Orforglipron, un agonista non peptidico del recettore GLP-1 per via orale, è stato associato alla riduzione del peso (75) e al miglioramento del diabete di tipo 2 (DMT2) (76).”
BackgroundTwin- und Trinkretine: Balanceakt zwischen Diabetes und Adipositas?
Stirban, O. A. (2024) · Info Diabetologie · doi:10.1007/s15034-023-4900-z
Lin, C.-M., Chen, J.-C., Huang, Y., & Su, P. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4845143
Childhood Weight Management in Practice
Stewart, L. (2024) · Child and Adolescent Obesity · doi:10.1002/9781119798873.ch11
Brown, H. M., Spies, N. C., Jia, W., Moley, J. R., Lawless, S., Roemmich, B., Brestoff, J. R., Zaydman, M. A., & Farnsworth, C. W. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae091 · Cited by 1
Cardiologia Teoria e Prática - Edição XVI
Freitas, G. B. L. D., & de Almeida, C. C. (2024) · doi:10.59290/978-65-6029-157-7
Grelewicz, O., Juśkiewicz, A., Servaas, E., Haber, M., Kula, P., Kotula, A., Czachor, A., & Kucy, N. (2024) · Quality in Sport · doi:10.12775/qs.2024.25.54915
Matsumi, Y., Kikuchi, S., Shoji, R., Teraishi, F., & Fujiwara, T. (2024) · Cureus · doi:10.7759/cureus.71401
Farmaci innovativi per il trattamento dell’obesità
Masi, D., Tuccinardi, D., & Watanabe, M. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01535-3 · Cited by 1
“Uno studio di fase 2 condotto su persone con obesità trattate per 36 settimane con orfor-glipron alla dose di 12–45 mg ha portato a una perdita di pe-so dose-dipendente fino al 14,7% rispetto al 2,3% con placebo, con un miglioramento concomitante dei fattori di ri-schio cardiometabolico [16].”
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, J., Liu, Y., & Jia, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0417
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Choi, J. H., & Moon, M. K. (2024) · Public Health Weekly Report · doi:10.56786/phwr.2024.17.44.4
“In contrast, orforglipron is a non-peptide formulation that can be taken irrespective of meals, offering fewer restrictions and comparable hypoglycemic and weight-loss effects than those of conventional GLP-1 receptor agonist injections [ 44 , 45 ].”
NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023
Lin, D. W., Armstrong, M., Jiang, J. B., del Pozo, J., & Teijaro, C. N. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch18
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes Care · doi:10.2337/dci24-0092 · Cited by 3
Urbańska, K., Popiela, D., Stojak, Ł., Kwiatkowski, F., Grego, K., Grego, M., Baczewski, M., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57002
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Kuczapska, K., Kurowski, M., Gliwa, A., Ryglewicz, M., Fabian, D., Leszczyńska-Knaga, E., Jakubczyk, N., Rutkowska-Kawalec, W., Moczydłowski, P., & Michalczuk, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.57095
A GLP-1-receptoragonistákon túl – az elhízás modern kezelési lehetőségei
Sztanek, F., & Tóth, L. I. (2024) · Diabetologia Hungarica · doi:10.24121/dh.2024.17
Efeitos do Orforglipron no tratamento da obesidade: revisão sistemática e metanálise
de Magalhães, M. J. D. S., de Souza, P. H. M., & Silva, V. T. O. F. (2025) · Bionorte · doi:10.47822/bn.v13i2.1045
Browning, T. E., Coy, A., Sehgal, V., Singh, S., Jakhar, N. S., Sehgal, P., & Kukreja, M. (2025) · doi:10.25259/peak_19_2024 · Cited by 1
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
Metadata
- Authors
- Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., & Konig, M.
- Affiliations
- Eli Lilly (United States) (US)
- From McMaster University, York University, and Wharton Weight Management Clinic — all in Toronto (S.W.); Texas Diabetes and Endocrinology, Austin (T.B.), and Velocity Clinical Research at Medical City, Dallas (J.R.) — both in Texas; Alliance for Multispecialty Research, Norman, OK (L.C.); and Eli Lilly, Indianapolis (S.R., R.L., X.M., K.J.M., A.H., D.R., E.P., C.K., M.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-07
- Volume
- 389
- Issue
- 10
- Pages
- 877-888
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4381716537
- Semantic Scholar
- db8284957df7f480bc8b5957f73388bfd42590cf
- Cited by
- 478
- References
- 19
- Citations by year
- 2026: 125 · 2025: 175 · 2024: 133 · 2023: 45
- FWCI
- 74.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, obesity, weight loss, cardiometabolic risk, gastrointestinal adverse effects, dose escalation, overweight adults, weight change, drug safety and efficacy, weight-related comorbidities, dose-response relationship, dose-limiting adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.